258 results
CORRESP
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
3 Feb 06
Correspondence with SEC
12:00am
FOR RETURN LOSSES, ONTAK END-CUSTOMER RETURNS,
MEDICAID REBATES, GOVERNMENT CHARGEBACKS, MANAGED HEALTH CARE REBATES AND OTHER
CONTRACT DISCOUNTS, PAGES 118 …
analysis accordingly.
RESPONSE:
For the Company's allowances for ONTAK end-customer returns, government
chargebacks and other
8-K/A
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
10 Dec 20
Financial Statements and Exhibits
4:13pm
and, where applicable, accrued profit related to long-term government contracts for which revenue has been recognized, but the customer has not yet … assets include customer relationships, developed technology and trade names related to the Company’s asset acquisition and have been capitalized
8-K/A
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
11 Apr 11
Financial Statements and Report of Independent Certified Public Accountants
12:00am
, several factors are taken into consideration, including historical write-off experience and review of specific customer accounts for collectibility … at the time the related inventory purchased is ultimately sold to a customer. The total deferred charge was $764,261 and $1 million at December 31, 2010
8-K/A
EX-99.1
hrmalaruv6psauj
12 Apr 11
Financial Statements and Report of Independent Certified Public Accountants
12:00am
8-K
EX-2
ikxf2efz82lqlfn2j6k9
28 Feb 07
Completion of Acquisition or Disposition of Assets
12:00am